文献速递银屑病与炎症性皮肤病

IL-36 在严重银屑病中促进系统性 I 型干扰素应答

IL-36 Promotes Systemic IFN-I Responses in Severe Forms of Psoriasis.
PubMed 文献 · J Invest Dermatol · 2019-09-17

本研究探讨 IL-36 过度活性对循环免疫细胞的影响,聚焦于广泛性脓疱型银屑病(GPP)和严重寻常型银屑病(PV)。通过血细胞和中性粒细胞 RNA 测序,发现患者存在显著的 IFN-I 特征,且与异常 IL-36 活性相关;机制上 IL-36 直接作用于浆细胞样树突状细胞,通过上调 PLSCR1 增强 TLR-9 活化及 IFN-α 产生。

要点

  • 严重银屑病患者外周血显示 IFN-I 特征,与 IL-36 活性异常相关。
  • IFN-I 基因激活与 GPP 和 PV 的皮外并发症相关。
  • IL-36 通过上调 PLSCR1 增强 pDC 中 TLR-9 介导的 IFN-α 产生。

核心结论

  • IL-36 通过直接作用于浆细胞样树突状细胞促进系统性 IFN-I 应答,形成 IL-36/IFN-I 轴参与银屑病皮外炎症。

研究设计与样本

  • 研究对 GPP 和严重 PV 患者进行血细胞和中性粒细胞 RNA 测序,并开展机制实验验证 IL-36 对 pDC 的作用。

主要发现

  • GPP 患者血细胞和中性粒细胞 RNA 测序显示显著 IFN-I 特征,且与异常 IL-36 活性相关。
  • 严重 PV 患者中验证了 IL-36 失调与 IFN-I 过表达的关联。
  • GPP 和 PV 中 IFN-I 基因激活均与皮外并发症相关。
  • 机制实验表明 IL-36 直接作用于 pDC,增强 TLR-9 活化和 IFN-α 产生。
  • 该效应由 PLSCR1 上调介导,PLSCR1 参与内体 TLR-9 转位。

临床怎么用

  • 在严重银屑病(尤其 GPP 和严重 PV)中应关注系统性 IFN-I 应答及皮外并发症风险。
  • IL-36/IFN-I 轴可能为干预银屑病系统性炎症提供潜在靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Psoriasis is an immune-mediated skin disorder associated with severe systemic comorbidities. Whereas IL-36 is a key disease driver, the pathogenic role of this cytokine has mainly been investigated in skin. Thus, its effects on systemic immunity and extracutaneous disease manifestations remain poorly understood. To address this issue, we investigated the consequences of excessive IL-36 activity in circulating immune cells. We initially focused our attention on generalized pustular psoriasis (GPP), a clinical variant associated with pervasive upregulation of IL-36 signaling. By undertaking blood and neutrophil RNA sequencing, we demonstrated that affected individuals display a prominent IFN-I signature, which correlates with abnormal IL-36 activity. We then validated the association between IL-36 deregulation and IFN-I over-expression in patients with severe psoriasis vulgaris (PV). We also found that the activation of IFN-I genes was associated with extracutaneous morbidity, in both GPP and PV. Finally, we undertook mechanistic experiments, demonstrating that IL-36 acts directly on plasmacytoid dendritic cells, where it potentiates toll-like receptor (TLR)-9 activation and IFN-α production. This effect was mediated by the upregulation of PLSCR1, a phospholipid scramblase mediating endosomal TLR-9 translocation. These findings identify an IL-36/ IFN-I axis contributing to extracutaneous inflammation in psoriasis.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Catapano M, Vergnano M, Romano M, et al. IL-36 Promotes Systemic IFN-I Responses in Severe Forms of Psoriasis. J Invest Dermatol. 2019. PMID: 31539532. doi:10.1016/j.jid.2019.08.444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。